本文選題：脊髓灰質(zhì)炎病毒 + Sabin株　； 參考：《昆明醫(yī)學(xué)院》2006年碩士論文

【摘要】：脊髓灰質(zhì)炎(poliomyelitis)(脊灰)是一種傳播廣泛、侵犯中樞神經(jīng)系統(tǒng)的病毒性傳染病，自1988年實(shí)施消滅脊髓灰質(zhì)炎(脊灰)戰(zhàn)略以來，我國通過接種口服脊髓灰質(zhì)炎減毒活疫苗(OPV)消滅了本土野毒株引起的脊髓灰質(zhì)炎。但是仍存在OPV引起的疫苗相關(guān)麻痹病例(VAPP)和疫苗衍生株(VDPV)，脊髓灰質(zhì)炎滅活疫苗(IPV)基本可避免OPV上述缺點(diǎn)。WHO指出當(dāng)全球證實(shí)消除脊灰后，，將停止使用OPV，屆時(shí)可能需要脊髓灰質(zhì)炎滅活疫苗(IPV)來長期保持脊灰免疫水平。相對(duì)于野毒株IPV，Sabin株IPV在制造和使用過程中更安全，對(duì)它的研究受到了WHO的高度重視。目前生產(chǎn)減毒株滅活疫苗的國家有中國、日本及荷蘭。我所正在積極研制Sabin IPV，D抗原量是體外測(cè)定IPV效力的關(guān)鍵指標(biāo)，與疫苗在人體內(nèi)免疫效力有較好的一致性。目前國際上尚缺乏Sabin IPV D抗原檢測(cè)的標(biāo)準(zhǔn)化的試劑，本實(shí)驗(yàn)應(yīng)用雜交瘤技術(shù)所制備的抗Ⅱ型Sabin株D抗原單克隆抗體分子量為150KD；純化抗體的ELISA效價(jià)為1：2.4×10~6，中和抗體效價(jià)為1：1.3×10~4；與Ⅱ型Sabin株C抗原、Ⅰ型、Ⅲ型Sabin病毒抗原不發(fā)生交叉反應(yīng)，特異性良好。并用此單克隆抗體的ELISA法與本室建立的多抗方法進(jìn)行比較，同時(shí)對(duì)三價(jià)Sabin IPV疫苗中Ⅱ型D抗原的含量進(jìn)行測(cè)量，發(fā)現(xiàn)在0.125Du／ml-2 Du／ml范圍內(nèi)應(yīng)用單抗測(cè)量D抗原的直線相關(guān)系數(shù)為0.998、0.966、0.903；而使用本室建立的多抗方法直線相關(guān)系數(shù)為1.000、0.998、0.986。本實(shí)驗(yàn)制備的單克隆抗體具有良好的特異性，可為Sabin IPV體外效力檢測(cè)的標(biāo)準(zhǔn)化奠定基礎(chǔ)。
[Abstract]:Poliomytis poliomyelitis (poliomyelitis) is a viral infectious disease that is widely spread and invades the central nervous system. Since the implementation of the poliomyelitis (polio) eradication strategy in 1988,Our country eliminated poliomyelitis caused by native wild strain by inoculating oral live attenuated poliomyelitis vaccine (OPVV).But there are still vaccine-related paralysis cases caused by OPV) and the vaccine derived strain, poliomyelitis inactivated vaccine, which can basically avoid the above-mentioned disadvantages of OPV. Who points out that when polio is confirmed to be eliminated globally,OPVs will be discontinued, when polio inactivated vaccine IPV may be required to maintain polio immunization over the long term.Compared with the wild strain IPV Sabin strain IPV is safer in manufacture and use, and its research has been paid more attention to by WHO.Currently, China, Japan and the Netherlands are producing attenuated inactivated vaccines.Our institute is actively developing Sabin IPV D antigen, which is the key index to determine the potency of IPV in vitro, and is in good agreement with the immune efficacy of the vaccine in human body.At present, there is a lack of standardized reagent for the detection of Sabin IPV D antigen in the world.The molecular weight of monoclonal antibody against D antigen of type 鈪

本文編號(hào)：1766801